[Form 4] Enova International, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Enova International insider transaction by CEO David Fisher: The filing shows Mr. Fisher, who is both Chief Executive Officer and a director, completed offsetting transactions on 08/26/2025. He acquired 5,000 shares via exercise at an exercise price of $23.96, bringing his beneficial ownership to 353,223 shares. On the same date he sold 5,000 shares under a Rule 10b5-1 plan at a weighted average price of $117.8003, reducing post-transaction shares to 348,223. The sale executed in multiple trades at prices between $114.27 and $118.57. The filing also discloses the structure and vesting of related options and limited SARs and notes the option vesting schedule in 2020–2022.

Positive

• Transparent disclosure of the sale as executed under a Rule 10b5-1 trading plan
• Exercise of options at a relatively low exercise price ($23.96) increasing share ownership to 353,223
• Detailed execution pricing provided (trades ranged $114.27–$118.57; weighted avg $117.8003) and offer to supply full trade details on request

Negative

• Disposition of 5,000 shares reduced holdings to 348,223, indicating insider liquidity on that date
• Complex compensation mechanics (paired SAR and option with change-in-control triggers) may complicate simple interpretation of insider incentives

Insights

Financial Analyst

TL;DR: Offsetting exercise and sale by CEO increased net shares modestly; proceeds likely realized while retaining substantial ownership.

The filing documents a simultaneous exercise of options and an executed sale under a Rule 10b5-1 plan on 08/26/2025. The exercise price was $23.96 for 5,000 shares and the sale generated a weighted average of $117.8003 per share across multiple trades. Net beneficial ownership changed from 353,223 shares after exercise to 348,223 after the sale. For investors, this is a routine management liquidity event rather than a change in strategic position; the transactions are consistent with preplanned trading arrangements and disclosed option/SAR mechanics.

Corporate Governance Expert

TL;DR: Transactions were prearranged and disclosed; governance protocols (10b5-1) were followed and vesting history is disclosed.

The sale is expressly reported as effected pursuant to a Rule 10b5-1 trading plan and the filer commits to provide detailed execution prices on request. The filing also explains that the exercised option is paired with a limited SAR and describes triggering conditions for SAR exercise and the option vesting schedule (one-third increments on 02/12/2020, 2021, 2022). These disclosures align with good insider-trading governance and transparency practices.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fisher David

(Last) (First) (Middle)

C/O ENOVA INTERNATIONAL, INC.

175 W. JACKSON BOULEVARD, SUITE 600

(Street)

CHICAGO IL 60604

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enova International, Inc. [ ENVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock, par value $0.00001 per share	08/26/2025		M		5,000	A	$23.96	353,223	D
Common stock, par value $0.00001 per share	08/26/2025		S(1)		5,000	D	$117.8003(2)	348,223	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy) with limited SAR(3)(4)	$23.96	08/26/2025		M			5,000	(5)	02/12/2026	Common stock; par value $0.00001 per share	5,000	$0	160,562	D

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to Mr. Fisher's Rule 10b5-1 trading plan.

2. This transaction was executed in multiple trades at prices ranging from $114.27 to $118.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer full information regarding the number of shares and the prices at which the transaction was effected.

3. The limited stock appreciation right ("SAR") and employee stock option were granted in tandem. Accordingly, the exercise of one results in the expiration of the other. The SAR may be exercised only during the period beginning on the first day following the date that a "Change in Control" of Issuer occurs (as defined in the related grant agreement) and ending on the thirtieth day following such date. Upon exercise, the grantee shall be able to receive an amount equal to the product computed by multiplying (i) the excess of the "Offer Value Per Share" over the exercise price of the underlying option by (ii) the number of shares with respect to which the SAR is being exercised; provided, that such amount shall only be payable in the event an "Offer" is made.

4. The "Offer Value Per Share" means the average selling price of Issuer's common stock during the period of 30 days ending on the date on which the SAR is exercised. "Offer" means any tender offer or exchange offer for outstanding shares of Issuer representing at least 30% of the total voting power of the stock of Issuer, or an offer to purchase assets from Issuer that have a total gross fair market value equal to or more than 40% of the total gross fair market value of all of the assets of Issuer, other than an offer made by Issuer.

5. The options vested in substantially equal one-third increments on each of the following dates: February 12, 2020, February 12, 2021, and February 12, 2022.

	/s/ Sean Rahilly, as attorney in fact	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did ENVA insider David Fisher report on 08/26/2025?

The filing reports an exercise of 5,000 shares at $23.96 and a sale of 5,000 shares under a Rule 10b5-1 plan at a weighted average price of $117.8003.

How many Enova (ENVA) shares does David Fisher beneficially own after these transactions?

Following the transactions, Mr. Fisher beneficially owned 348,223 shares after the sale (and had held 353,223 immediately after the exercise).

Was the sale by the ENVA CEO part of a prearranged trading plan?

Yes. The filing states the sale was effected pursuant to Mr. Fisher's Rule 10b5-1 trading plan.

What prices were involved in the reported sale of ENVA shares?

The sale was executed in multiple trades at prices ranging from $114.27 to $118.57, with a reported weighted average sale price of $117.8003.

What is disclosed about the options and SARs in the filing?

The filing explains that the option and a limited SAR were granted in tandem (exercise of one expires the other), defines the SAR payout mechanics and change-in-control trigger, and discloses option vesting occurred in one-third increments on 02/12/2020, 02/12/2021, and 02/12/2022.